


RECEIPT \$

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents Washington, D.C. 20231  
on June 6, 2000  
By: Dori Flangas

PATENT  
Attorney Docket No.: 15280W003000

FILE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hyun K. Kim, *et al.*

Application No.: 09/526,855

Filed: March 17, 2000

For: STRUCTURAL MODIFICATION OF  
19-NORPROGESTERONE I: 17- $\alpha$ -  
SUBSTITUTED-11- $\beta$ -SUBSTITUTED-4-  
ARYL AND 21-SUBSTITUTED 19-  
NORPREGNADIENEDIONE AS NEW  
ANTIPROGESTATIONAL AGENTS

Examiner: Unassigned

Art Unit: 1615

REQUEST FOR CORRECTED FILING  
RECEIPT

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office in the above-noted application for which issuance of a corrected filing receipt is respectfully requested.

There are errors in the Applicant(s) names that should read as follows:

Carmie K. Acosta


Anne Marie Simmons

Also, the title should read as follows: STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17- $\alpha$ -SUBSTITUTED-11- $\beta$ -SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS

The correction is due to applicants' error and the fee therefor, pursuant to 37 CFR §1.19(h), of \$25 is to be charged to Deposit Account No. 20-1430. Please charge any additional

fees or credit overpayment to the Deposit Account No. 20-1430. This Petition is submitted in triplicate.

Respectfully submitted,

  
Eugenia Garrett-Wackowski  
Reg. No. 37,330

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
EGW/lis

SF 1101862 v1



Bib Data Sheet


**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

 Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

**FILE COPY**

SERIAL NUMBER 09/526,855	FILING DATE 03/17/2000 RULE -	CLASS 424	GROUP ART UNIT 1615	ATTORNEY DOCKET NO. 15280W003000
-----------------------------	-------------------------------------	--------------	------------------------	--

**APPlicants**

Hyun K. Kim, Bethesda, MD ;  
 Richard P. Blye, Highland, MD ;  
 Pemmaraju N. Rao, San Antonio, TX ;  
 James W. Cessac, San Antonio, TX ;  
 Carmie K. Acosta, San Antonio, TX ;  
 Anne Marie Simmons, San Antonio, TX ;

**\*\* CONTINUING DATA \*\*\*\*\***

THIS APPLICATION IS A CIP OF 09/180,132 05/24/1999  
 WHICH IS A 371 OF PCT/US97/07373 04/30/1997  
 AND CLAIMS BENEFIT OF 60/016,628 05/01/1996

RECEIVED  
JUL 13 2000  
U.S. Patent and Trademark Office

**\*\* FOREIGN APPLICATIONS \*\*\*\*\*****IF REQUIRED, FOREIGN FILING LICENSE GRANTED**

\*\* 05/18/2000

Foreign Priority claimed	<input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY	SHEETS DRAWING	TOTAL CLAIMS	INDEPENDENT CLAIMS
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> Met after Allowance	MD	11	50	1
Verified and Acknowledged	Examiner's Signature _____ Initials _____				

**ADDRESS**

20350

**TITLE**

Structural modification of 19-Norprogesterone I: 17-alpha-substituted-11-Beta-substituted-4-Aryl and 21-substituted 19-Norpregnadienedione as new Antiprogestational agents

FILING FEE RECEIVED 0	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
--------------------------	---	---

## FILING RECEIPT

  
\*OC00000005126352\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

EGW

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/526,855	03/17/2000	1615	0	15280W003000	11	50	1

20350  
 TOWNSEND AND TOWNSEND AND CREW LLP  
 TWO EMBARCADERO CENTER  
 EIGHTH FLOOR  
 SAN FRANCISCO, CA 94111

Date Mailed: 05/18/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Hyun K. Kim, Bethesda, MD ;  
 Richard P. Blye, Highland, MD ;  
 Pemmaraju N. Rao, San Antonio, TX ;  
 James W. Cessac, San Antonio, TX ;  
*Carmie* Carmie K. Acosta, San Antonio, TX ;  
 Marie-Simmon-Anne, San Antonio, TX ;  
 Anne Marie Simmons

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/180,132 05/24/1999  
 WHICH IS A 371 OF PCT/US97/07373 04/30/1997  
 AND CLAIMS BENEFIT OF 60/016,628 05/01/1996

## Foreign Applications

If Required, Foreign Filing License Granted 05/18/2000

## Title

Structural modification of 19-Norprogesterone I: 17- $\alpha$ -substituted-11- $\beta$ -substituted-4-Aryl and  
 21-substituted 19-Norpregnadienedione as new Antiprogestational agents

## Preliminary Class

424



Data entry by : BURNS, ERIC

Team : OIPE

Date: 05/18/2000



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

